Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion.
The pharmacokinetics of 5-fluorouracil (5-FU) injected into a surgically isolated pelvic circuit during hyperthermic perfusion was studied in five patients with local recurrence of anorectal cancer. 5-FU doses ranged from 11 to 23 mg/kg. The geometric mean ratio of peak plasma 5-FU in the isolated to systemic circuits was 10, the ratio at the end of the 45-minute perfusion was 12.5. The mean half-life of 5-FU in the isolated circuit was 18.5 minutes. Total drug exposure for the isolated circuit was 7.8-fold greater than for the systemic compartment. These results demonstrate a large pharmacologic advantage for the use of the isolation-perfusion technique.
D000230:Adenocarcinoma / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D005472:Fluorouracil / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D006801:Humans; D006979:Hyperthermia, Induced; D007700:Kinetics; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010386:Pelvic Neoplasms / Q000188:drug therapy*
D005472:Fluorouracil